Abstract
PurposeWe examine the levels of post-trial responsibility ascribed to different stakeholders, following a community-based clinical trial and how the ‘responsibility’ is understood.MethodsWe employed photovoice, unstructured observations and key informant interviews to gain insights into contexts of access to care following transition to the public health system post trial. We used an inductive narrative analysis to explore experiences and understandings of post-trial access (PTA).ResultsIn their photovoice stories, many participants expressed a sense of abandonment after the trial. This was viewed as a contributing factor to failing to re-engage with care available in the public health system. This led to the experiences of loss as some trial participants defaulted and died. Research investigators, department of health participants and sponsor agreed that PTA was especially important for communities in resource-limited settings. The government has an obligation towards its citizens while researchers have a responsibility to ensure a smooth transition of patients to public clinics. Sponsors have a responsibility to ensure that the trial is conducted in accordance with the protocol and post-trial agreements are in place and adhered to. Research partnerships among stakeholders were affected by power imbalances making it difficult to negotiate and plan for post-trial care responsibilities.ConclusionsThe research community still struggles with understanding the scope of PTA responsibilities. Power dynamics between public health actors and research sponsors need to be managed to ensure that government involvement is not tokenistic. The responsibility of trial participants and ethics committees needs to be investigated further.
Subject
Health Policy,Arts and Humanities (miscellaneous),Issues, ethics and legal aspects,Health (social science)
Reference26 articles.
1. Post-trial access and the new version of the Declaration of Helsinki;Palacios;Colomb Med,2013
2. Who should pay for the continuity of post-trial health care treatments?;Iunes;Int J Equity Health,2019
3. National Bioethics Advisory Commission . Ethical and policy issues in international research: clinical trials in developing countries volume I report and recommendations of the National bioethics Advisory Commission, 2001. Available: www.bioethics.gov
4. Post-trial access;Usharani;Perspect Clin Res,2013
5. Implementing post-trial access plans for HIV prevention research
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献